Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Mucosis Appoints Thomas Johnston to CEO

Published: Monday, September 17, 2012
Last Updated: Monday, September 17, 2012
Bookmark and Share
Mr. Johnston joined Mucosis as Chief Business Officer in May 2011, and succeeds Govert Schouten who is leaving the Company to found an internet start-up.

"Tom has more than 15 years of leadership experience in the biotech and other industries and has been an invaluable member of our executive management team," said John Lambert, Chairman of the Mucosis Board of Directors. "He has played a lead role in the ongoing rollout of our Mimopath platform licensing initiative and the development of our overall strategies for continued growth. Given Tom's substantial commercial experience and familiarity with the Company, we are confident he is the right person to lead Mucosis as we execute our strategy and further advance the development and commercialization of the Mimopath platform including our RSV vaccine candidate." Mr. Lambert continued, "I also would like to thank Govert Schouten for his leadership these past 4 years during which he helped transform Mucosis from a promising start-up into a clinical-stage biotech Company with a strong technology and product pipeline. We wish him the very best in his future endeavors."

Mr. Johnston said, "I am honored to be given this opportunity to take on the role of CEO of Mucosis during this exciting time in the Company's history. Over the past year, our team has completed a clinical proof of concept study in human influenza for the Mimopath platform while also advancing our lead vaccine program for the prevention of RSV into pre-clinical studies. These and other recent accomplishments position us very well in the biotech marketplace and I am confident that we will be able to execute on our plan to deliver sustainable results and drive long-term value for our shareholders."

Mr. Johnston joined Mucosis from Novavax Inc, a Nasdaq-listed clinical-stage biopharmaceutical company. As Vice President of Strategy there, he developed and executed a regional partnership strategy concluding deals in India, Mexico and South Korea. Prior to Novavax, Mr. Johnston served as an executive-level strategic consultant in a number of industries including biotech, and held various senior-level positions with a number of world-class organizations such as Comcast, Microsoft, and Schlumberger. Mr. Johnston holds an M.B.A. from The Wharton Business School and a Bachelor of Science degree in Computer Science from Arcadia University.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Mucosis Receives Financial Support from the Dutch Government
Company receives an innovation credit line of up to €5 million for its SynGEM® program.
Friday, May 23, 2014
Mucosis Announces a Strategic Partnership with Changchun BCHT Biotechnology
Company raises EUR 5 million in a new financing round.
Wednesday, April 16, 2014
ExpreS2ion, Mucosis, and University of Copenhagen Receive Eurostars Grant
Eurostars™ grant for the pre-clinical development of an innovative placental malaria vaccine.
Thursday, September 27, 2012
Mucosis Announces Positive Proof-Of-Concept Data for Mimopath® Platform in Humans
Mimopath®-based vaccines are able to produce balanced immune responses in both circulating blood and the respiratory tract.
Monday, May 14, 2012
Mucosis Announces Publication of Preclinical Data of Novel Influenza Vaccines
Mucosally administered Mimopath-based influenza vaccine protects against both homologous and heterologous challenge.
Thursday, May 03, 2012
Mucosis Announces New Scientific Advisory Board
Professors Jiri Mestecky, Willem van Eden and Peter J. Openshaw appointed to Scientific Advisory Board.
Friday, November 18, 2011
Mucosis Appoints Thomas Johnston as Chief Business Officer
Thomas Johnston will have global responsibility for the licensing and marketing of Mucosis’s technologies, negotiating corporate partnerships and other strategic alliances.
Monday, June 06, 2011
Mucosis Appoints Thomas Johnston as Chief Business Officer
Thomas have global responsibility for the licensing and marketing of Mucosis’s technologies, negotiating corporate partnerships and other strategic alliances.
Wednesday, May 18, 2011
Scientific News
Experimental MERS Vaccine Shows Promise in Animal Studies
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.
Sweet Revenge Against Superbugs
A special type of synthetic sugar could be the latest weapon in the fight against superbugs.
Researchers Develop Vaccine that Protects Primates Against Ebola
A collaborative team from The University of Texas Medical Branch at Galveston and the National Institutes of Health have developed an inhalable vaccine that protects primates against Ebola.
Universal Flu Vaccine in the Works
A new study has demonstrated a potential strategy for developing a flu vaccine with potent, broad protection.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Ferring Bets on Bacteriophages to Treat Inflammatory Bowel Disease
Ferring Pharmaceuticals have annoucned that it will collaborate with Intralytix in the latest phase of its early stage development programme for a bacteriophage-based therapy for inflammatory bowel disease (IBD).
A Novel Drug to FIght Malaria
An international team of scientists has announced that a new compound to fight malaria is ready for human trials.
Ebola Vaccine Trial Begins in Senegal
A clinical trial to evaluate an Ebola vaccine has begun in Dakar, Senegal, after initial research started at the Jenner Institute, Oxford University.
New Cell Structure Finding Might Lead to Novel Cancer Therapies
University of Warwick scientists in the U.K. say they have discovered a cell structure which could help researchers understand why some cancers develop.
Cancer Discovery Links Experimental Vaccine and Biological Treatment
A new study at the University of Wisconsin-Madison has linked two seemingly unrelated cancer treatments that are both now being tested in clinical trials.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!